Diffusion Magnetic Resonance Imaging (dMRI) in the Early Evaluation of Brain White Matter Diseases
The Role of Diffusion Magnetic Resonance Imaging (dMRI) in the Early Evaluation of Brain White Matter Diseases
The General Authority for Teaching Hospitals and Institutes
150 participants
May 1, 2025
OBSERVATIONAL
Conditions
Summary
To assess the sensitivity and accuracy of diffusion magnetic resonance imaging (MRI), including diffusion-weighted imaging (DWI) metrics, in identifying early-stage changes in brain white matter related to various white matter diseases.
Eligibility
Inclusion Criteria4
- Adults aged 18-80 years.
- Clinical suspicion of early-stage white matter disease.
- No prior diagnosis of significant neurological disorders (e.g., stroke, brain tumors).
- Ability to provide informed consent.
Exclusion Criteria4
- Pregnancy or breastfeeding.
- Contraindications for magnetic resonance imaging (MRI) (e.g., metal implants, pacemakers).
- Severe psychiatric or cognitive impairment that prevents participation.
- Control Group: Healthy individuals without any clinical history of neurological diseases, matched by age and sex to the patient cohort.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Magnetic Resonance Imaging (MRI) Scanner: All imaging will be performed using a 1.5 tesla MRI scanner to ensure high resolution and signal-to-noise ratio.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07108712